【摘要】 目的  應用門冬氨酸鳥氨酸對肝性腦病的臨床療效及安全性進行觀察。 方法  2000年4月-2009年11月，將60例肝硬化肝性腦病患者分為對照組和治療組，對照組給予常規精氨酸治療，治療組在對照組基礎上加門冬氨酸鳥氨酸10 g/d，靜脈滴注，連續7 d。觀察治療前后神志變化、血清氨基轉移酶(ALT、AST)、血清白蛋白(ALB)等指標變化。 結果  治療組經門冬氨酸鳥氨酸治療后神志改變、ALT、AST明顯優于治療前（P lt;0.05）。 結論  門冬氨酸鳥氨酸治療肝性腦病療效確切，且對肝功能有改善作用，副反應小。
【Abstract】 Objective  To evaluate the clinical efficacy and safety of L-ornithine-L-aspartate treating the patients with hepatic encephalopathy. Methods  Sixty patients with hepatic encephalopathy from April 2000 to November 2009 were randomly divided into treatment group and control group with 30 patients in each. The patients in the control group were treated with the routine therapy of arginine, while the ones in the treatment group were treated with L-ornithine-L-aspartate besides the routine therapy for one week injection (10.0 g dissolved in 5% glucose 250 mL by intravenous infusion once daily), the liver function and mind change were observed in all patients at the onset and one week after treatment respectively. Results  One week after the treatment, the liver function (ALT, AST) and mind change of patients differed statistically significantly from that before the treatment (P lt;0.05). Conclusion  L-ornithine-L-aspartate is effective for the patients with minimal hepatic encephalopathy, which could improve the liver function with little side effect.

Citation： CHEN Ju. Clinical Analysis of L-ornithine-L-aspartate Treating Hepatic Encephalopathy. West China Medical Journal, 2010, 25(9): 1602-1603. doi: Copy

Copyright ? the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved